Scilex Holding Company Ordinary Shares SCLX 深 滬
已收盤 08-01 16:00:00 美东时间
13.41
-0.010
-0.07%
華盛通- 最 高13.9799
- 今 開12.98
- 成交量 14.63万股
- 最 低 12.71
- 昨 收 13.42
- 總市值 9322.10万
- 52周最高 49.00
- 市盈率 靜 --
- 換手率 2.11%
- 52周最低 3.60
- 委 比 0.00%
- 總股本 695.16万
- 歷史最高 591.50
- 量 比 0.33
- 振 幅 9.46%
- 歷史最低 0.00
- 每 手 1
- 風險率 13.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 公司获高额股权融资，VWAV飙涨近370%；CELC大涨超167%
公司获高额股权融资，VWAV飙涨近370%；乳腺癌药物实验效果积极，CELC大涨超167%；正式进军稳定币领域，MPU大涨超40%>>
07-29 19:19
Oramed Grants Scilex $27M Option To Repurchase Warrants, With Potential Note Extension To 2026
As previously disclosed, on September 21, 2023, Oramed Pharmaceuticals Inc. (the "Company") entered into and consummated the transactions contemplated by a Securities Purchase Agreement (as amended by that certain
07-23 21:47
Scilex Holding Company Concludes 2025 Annual Stockholders Meeting
An announcement from Scilex Holding Company ( ($SCLX) ) is now available. On Ju...
06-24 04:37
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board
Scilex Holding Company, headquartered in Palo Alto, California, announced that its Board of Directors has deferred the previously announced record date of May 2, 2025, for its preferred stock dividend to stockholders. The new record date will be determined at the Board's discretion, with the right to change or revoke the dividend. Scilex focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chroni...
06-23 20:50
Scilex Holding Announces Publication On GLOPERBA Dosing Adjustments In Peer-Review Journal
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
06-06 00:10
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
Scilex Holding Company announced a peer-reviewed publication on GLOPERBA® dosing adjustments, particularly for patients with renal impairment. GLOPERBA®, the only liquid oral colchicine for gout flare prophylaxis, allows precise dosing to minimize toxicity risks. The study highlights optimal dosing levels for moderate (0.48 mg) and severe (0.3 mg) renal impairment, improving safety. The company focuses on non-opioid pain management products, incl...
06-05 16:05
Scilex Holding Presents Post-Hoc Analysis of C.L.E.A.R. Trial On Clinical Meaningfulness Of Safety And Efficacy Of SP-102 For Treatment of Lumbosacral Radicular Pain at ASIPP 2025
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
05-16 21:21
Scilex Updates Director Compensation Following Stock Split
Scilex Holding Company ( ($SCLX) ) has issued an announcement. On April 15, 202...
05-12 21:18
What Does the Market Think About Scilex Holding?
Scilex Holding's (NYSE:SCLX) short percent of float has fallen 4.27% since its ...
04-16 03:00
Scilex to conduct reverse stock split
Scilex (NASDAQ:SCLX) said it will implement a reverse stock split at a ratio of 1-for-35, to be effective on April 15. The split will help the company regain compliance with Nasdaq's minimum bid price...
04-11 21:03
